Information about CORGA

COMPOSITION:
Each tablet contains 40 or 80 mg Nadolol.
PHARMACOLOGICAL CLASS:
Nadolol is a nonselective beta-adrenergic receptor blocking agent.
PHARMACOKINETICS:
Absorption of nadolol after oral dosing is variable, averaging about 30 percent. Peak serum concentrations of nadolol usually occur in three to four hours after oral administration and the presence of food in the gastrointestinal tract does not affect the rate or extent of nadolol absorption. Approximately 30 percent of the nadolol present in serum is reversibly bound to plasma protein.
Unlike many other beta-adrenergic blocking agents, nadolol is not metabolized by the liver and is excreted unchanged, principally by the kidneys. The half-life of therapeutic doses of nadolol is about 20 to 24 hours, permitting once-daily dosage.
INDICATIONS:
Angina Pectoris:
Nadolol is indicated for the long-term management of patients with angina pectoris.
Hypertension:
Nadolol may be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics.
CONTRAINDICATIONS:
Nadolol is contraindicated in: bronchial asthma, sinus bradycardia and greater than first degree conduction block, cardiogenic shock, and overt cardiac failure.
DOSAGE AND ADMINISTRATION:
Angina Pectoris:
The usual initial dose is 40 mg nadolol once daily. Dosage may be gradually increased in 40 to 80 mg increments at 3 to 7 days intervals until optimum clinical response is obtained or there is pronounced slowing of the heart rate. The usual maintenance dose is 40 or 80 mg administered once daily. Doses up to 160 or 240 mg administered once daily may be needed. The usefulness and safety in angina pectoris of dosage exceeding 240 mg per day have not been established. If treatment is to be discontinued, reduce the dosage gradually over a period of one to two weeks.
Hypertension:
The usual initial dose is 40 mg nadolol once daily, whether it is used alone or in addition to diuretic therapy. Dosage may be gradually increased in 40 to 80 mg increments until optimum blood pressure reduction is achieved. The usual maintenance dose is 40 or 80 mg administered once daily. Doses up to 240 or 320 mg administered once daily may be needed.
SIDE EFFECTS:
Most adverse effects have been mild and transient and have rarely required withdrawal of therapy.
Bradycardia with heart rates of less than 60 beats per minute occurs commonly. Symptoms of peripheral vascular insufficiency, usually of the Raynaud type, have occurred in approximately 2 of 100 patients. 
Cardiac failure, hypotension, and rhythm/conduction disturbances have each occurred in about 1 of 100 patients. Single instances of first degree and third degree heart block have been reported.
Dizziness or fatigue has been reported in approximately 2 of 100 patients; paresthesia, sedation, and change in behavior have each been reported in approximately 6 of 1000 patients. Bronchospasm has been reported in approximately 1 of 1000 patients.
STORAGE CONDITION: 
Store below 30°C. Away from light and excessive heat.
PACKAGING: 
Carton Pack of 30 tablets.